Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy initiates Phase I on respiratory inflammation compound

This article was originally published in Scrip

Executive Summary

Ranbaxy Laboratorieshas initiated Phase I clinical studies in India and Europe on a lead compound for respiratory inflammation under its collaborative research programme withGlaxoSmithKline. Ranbaxy, now a subsidiary of Daiichi Sankyo, is expected to receive a milestone payment for beginning Phase I studies. Ranbaxy is also responsible for conducting Phase II clinical studies through to proof-of-concept (Phase IIa), after which GSK will have the option to conduct further development through to final commercialisation. The Ranbaxy/GSK collaboration began in 2003 and was expanded in February 2007. The expanded agreement gave Ranbaxy additional drug development responsibilities and further financial opportunities. Ranbaxy could receive more than $100 million in potential milestone payments for a product developed by it and subsequently launched by GSK in multiple indications and up to double-digit royalties on worldwide net sales. The alliance is working on programmes in the areas of anti-infectives, respiratory and oncology indications.

Topics

Related Companies

UsernamePublicRestriction

Register

SC008050

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel